Answers are grounded in this paper and cite their sources.
Background: Thymoma-associated stiff-person spectrum disorder (SPSD) with anti-glycine receptor (GlyR) antibodies is exceedingly rare, and evidence guiding its management remains limited. Case presentation: A 49-year-old woman with a type B1 thymoma presented with one month of progressive dysphagia, bilateral ptosis, restricted eye movement, and lower-limb stiffness. Anti-GlyR1-IgG, anti-GAD65-IgG, and anti-GAD67-IgG were detected in both serum and cerebrospinal fluid, with additional muscle-type anti-acetylcholine receptor (AChR)-IgG positivity in serum, and electrophysiology demonstrated widespread neuromuscular junction involvement. Thymectomy followed by first-line immunotherapy (corticosteroids, intravenous immunoglobulin, and mycophenolate mofetil) produced only partial improvement. An individualized low-dose rituximab regimen (500 mg every 6 months) was then initiated. Over 24 months and five infusions, anti-GlyR1-IgG and AChR-IgG became undetectable, whereas anti-GAD65/67-IgG persisted and rose modestly (GAD65 from 1:100 to 1:300) without clinical worsening. Independent ambulation was achieved on July 11, 2024, and the patient remained relapse-free during follow-up. Persistent hypogammaglobulinemia developed, without serious infections. Conclusions: This case highlights the diagnostic complexity of thymoma-associated stiff-person spectrum disorder with multiple autoantibodies. Clinical outcomes and treatment safety should guide the interpretation of serial antibody findings.
No takes yet. Share an insight, caveat, or question.
Zhong et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: